Revvity will hold its earnings call on Friday, January 31, 2025; Provides the latest information on Investing.com’s financial results

WALTHAM, Mass.–( BUSINESS WIRE )–Revvity, Inc. (NYSE: RVTY ), today announced that it will report financial results for the fourth quarter and full year 2024 before the market opens on Friday, January 31, 2025. The company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, President and Chief Executive Officer, and Max Krakowiak, Chief Financial Officer, will host the conference call.

A live audio webcast of the call will be available to access through this registration form or on the investor section of the Company’s website.

Updating financial results

The Company also announces the following preliminary financial results for the fourth quarter of 2024:

• Reported and organic revenue growth for the fourth quarter is expected to be approximately 5% and 6%, respectively, compared to the same period a year ago. This is expected to result in fourth quarter revenue of approximately $730 million.

The company now also expects its full-year 2024 adjusted earnings per share to meet or exceed guidance dated November 4, 2024.

JP Morgan Healthcare Conference

As previously announced, Prahlad Singh will be presenting at JP Morgan’s 43rd Annual Healthcare Conference tomorrow (January 13, 2025) at 8:15 AM PT. A live audio broadcast of the presentation will be available through this page. A copy of the accompanying slide presentation will be available in the investor section of the Company’s website.

Use of non-GAAP financial measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. The reasons we use these measures, the reconciliation of those measures to the most directly comparable GAAP measures and other information relating to those measures are included below under Explanation of Non-GAAP Financial Measures.

The adjusted earnings per share guidance for the full year 2024 is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without reasonable effort due to the unpredictability of the amount and timing of events affecting the items the Company excludes from these non-GAAP measures. GAAP measures. The timing and amounts of such events and items may be material to the Company’s results prepared in accordance with GAAP.

Factors affecting future performance

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future adjusted earnings per share, revenue, growth income and other financial results. Words such as “believes”, “intends”, “anticipates”, “plans”, “expects”, “estimates”, “projects”, “anticipates”, “will” and similar expressions, and references to guidance, are intended identify forward-looking statements. Such statements are based on management’s current assumptions and expectations, and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from those described, implied or projected in any forward-looking statements. These factors include, without limitation: the completion of quarterly and year-end closing procedures for the fourth quarter and fiscal year ended December 29, 2024 and other factors that we describe under the heading “Risk Factors” in our most recent Quarterly Report on Form 10 – Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments after the date of this press release.

About Revvity

At Revvity, the impossible is inspiration and the impossible is a call to action. Revvity provides health science solutions, technologies, expertise and services that provide complete workflows from discovery to development and diagnosis to treatment. Revvity is revolutionizing what’s possible in healthcare, with specialized areas of focus in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With revenues of more than $2.7 billion in 2023 and over 11,000 employees, Revvity serves clients in pharmaceutical and biotechnology, diagnostic laboratories, academia and government. It is part of the S&P 500 index and has clients in more than 190 countries.

Stay up to date by following our News, LinkedInX, YouTube, Facebook (NASDAQ:) and Instagram.

Explanation of non-GAAP financial measures

We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operating trends, investors may want to consider the impact of certain non-cash, non-recurring or other items arising from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures in addition to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with an additional means of understanding and evaluating operating results and trends in our current operations by adjusting for certain non-cash expenses and other items that management believes would otherwise make comparisons of our current operations with prior periods. difficult, unclear trends in ongoing operations or reduce management’s ability to make useful forecasts. Management believes that these non-GAAP financial measures provide an additional means of evaluating operating performance compared to the prior period. In addition, management understands that some investors and financial analysts find this information useful in analyzing our financial and operating performance and comparing that performance to our competitors and competitors.

We use the term organic revenue to refer to GAAP revenue excluding the effect of foreign currency changes and revenue from recent acquisitions and divestments and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term organic revenue growth or organic growth to refer to a measure of how the current period’s organic revenue compares to the corresponding period in the prior year.

Management includes or excludes the effect of the item identified below in the applicable non-GAAP financial measure above for the reasons set forth below in connection with that item:

• Revenues from contracts acquired in acquisitions that will not be fully recognized due to accounting rules ” accounting rules require us to account for the fair value of revenue from contracts assumed in connection with our acquisitions. As a result, our GAAP results reflect the fair value of those revenues, which is not the same as the revenue that would otherwise be recorded by the acquiree. We include such revenues in our non-GAAP measures because we believe that the fair value of such revenues does not accurately reflect the performance of our ongoing operations for the period in which such revenues are recorded.

The non-GAAP financial measures described above are not intended to be considered superior to or a substitute for our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude expenses that affect our reported results and therefore should not be relied upon as the sole financial measures by which we evaluate our financial results. Management compensates for, and believes investors should compensate for, these limitations by looking at non-GAAP financial measures in conjunction with GAAP financial measures. Furthermore, non-GAAP financial measures included in this earnings release may differ from similar measures used by other companies and therefore may not be comparable.

Each non-GAAP financial measure listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, compare our results to our historical performance and that of our peers, evaluate investment opportunities including acquisitions and business discontinuations, and determine bonus payments for senior management and employees.

See the original version on businesswire.com: https://www.businesswire.com/news/home/20250112188630/en/

Relations with investors:
Steve Willoughby
steve.willoughby@revvity.com

Relations with the media:
Chet Murray
(781) 462-5126
chet.murray@revvity.com

Source: Revvity